ReviewCancer reports (Hoboken, N.J.)2025
Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Immune Checkpoint Inhibitors in Cancer Patients With Concurrent Active Tuberculosis: A Real-World Study in a High Tuberculosis Burden Region.Open forum infectious diseases · 2026Article
- Beyond Cure: A Scoping Review of Post-Tuberculosis Long-Term Health Outcomes.Tropical medicine and infectious disease · 2026Review
- Tuberculosis meningoencephalitis mimicking lung cancer with metastasis: a case report.Encephalitis (Seoul, Korea) · 2026Article
- Clinical characteristics and surgical outcomes of uniportal video-assisted thoracoscopic surgery for lung cancer patients with concomitant pulmonary tuberculosis: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Post-Tuberculosis Sequelae and Active Tuberculosis in Lung Cancer: Imaging Patterns and Clinical Associations-A Retrospective Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- Long-term risk of death after tuberculosis diagnosis and treatment.Nature medicine · 2026Article
- Development and validation of a habitat-based computed tomography radiomics model for differentiating isolated lung cancer, isolated tuberculoma, and coexistence of tuberculosis with lung cancer: a dual-center retrospective study.Translational lung cancer research · 2026Article
- Scars That Speak: Unraveling the Oncogenic Aftermath of Pulmonary Tuberculosis-A Narrative Review.Journal of clinical medicine · 2026Review
- NLRC4 and NLRP3 in tissues as potential biomarkers for the diagnosis of non-small cell lung cancer in pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2026Article
- Review
- Molecular links between tuberculosis and lung cancer: pathogenesis and therapeutic challenges.Archives of microbiology · 2025Review
- Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral.Frontiers in cellular and infection microbiology · 2025Review
- Establishment and validation of a convenient and efficient screening tool for active pulmonary tuberculosis in lung cancer patients based on common parameters.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlobally, infections account for 10% of new cancer cases, and cancer can compromise the immune system, increasing the risk of infections. With advances in cancer treatment, widespread use of immunotherapy, and prolonged survival of cancer patients, the coexistence of tuberculosis (TB) and cancer is becoming increasingly common in clinical settings.
aimThis review aims to explore the interaction between tuberculosis (TB) and tumors, particularly lung cancer (LC), and to identify appropriate clinical management approaches.
resultsLC patients with a history of TB have higher adjusted risk ratios for both all-cause and cancer-specific 3-year mortality compared to those without a history of TB. TB may elevate the risk of developing tumors through mechanisms such as chronic inflammation, altered immune responses, and DNA damage. Conversely, cancer patients, whether due to the disease itself or immune dysfunction caused by anti-tumor treatments, may be more susceptible to TB. The coexistence of TB and tumors presents significant challenges in clinical management, making the development of treatment strategies and quality-of-life improvements crucial.
conclusionThere is a close relationship between TB and cancer, with TB potentially serving as a risk factor for cancer, and cancer influencing susceptibility to TB. Effective clinical management is essential to enhance treatment strategies and improve the quality of life for patients with both TB and cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.